NWPHF OTC
Newron Pharmaceuticals S.p.A.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
$20.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$18M
-73.7% ▼
Capital Expenditures
$13K
-18.2% ▼
5Y CAGR: -23.9%
Free Cash Flow
-$18M
-73.6% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$595K
+108.4% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$21M | -$15M | -$17M | -$16M | $21M |
| Depreciation & Amort. | $219K | $209K | $202K | $201K | $192K |
| Stock-Based Comp. | $1M | $762K | $480K | $197K | $256K |
| Change in Working Capital | $1M | $2M | -$882K | $2M | -$38M |
| Other Non-Cash Items | $5M | $3M | $6M | $4M | -$2M |
| Operating Cash Flow | -$16M | -$11M | -$11M | -$10M | -$18M |
| — Investing Activities — | |||||
| Capital Expenditures | -$34K | -$20K | -$18K | -$11K | -$13K |
| Acquisitions (Net) | $581K | -$8M | $299K | -$3M | $0 |
| Investment Purchases | -$2M | -$2M | -$3M | -$981K | -$2M |
| Investment Sales | $2M | $10M | $3M | $4M | $5M |
| Other Investing | -$582K | $8M | -$299K | $3M | $0 |
| Investing Cash Flow | -$616K | $8M | -$317K | $3M | $3M |
| — Financing Activities — | |||||
| Net Debt Issuance | $8M | $15M | $0 | $0 | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$135K | -$169K | -$186K | -$192K | -$363K |
| Financing Cash Flow | $7M | $15M | -$186K | -$192K | $15M |
| Net Change in Cash | -$9M | $12M | -$12M | -$7M | $595K |
| Cash End of Period | $13M | $25M | $13M | $6M | $7M |
| Free Cash Flow | -$16M | -$11M | -$11M | -$10M | -$18M |